AU Patent

AU2023213780B2 — Crystal form and salt of phenothiazine compound, preparation method therefor and use thereof

Assigned to Chengdu Henghao Innovative Science And Technology Co Ltd · Expires 2025-11-13 · 1y expired

What this patent protects

Provided are a crystal form and salt of a phenothiazine compound, a preparation method therefor and a use thereof. A hydrochloride of the phenothiazine compound and a crystal thereof can be used as ferroptosis inhibitors, and the hydrochloride and the crystal thereof have relativ…

USPTO Abstract

Provided are a crystal form and salt of a phenothiazine compound, a preparation method therefor and a use thereof. A hydrochloride of the phenothiazine compound and a crystal thereof can be used as ferroptosis inhibitors, and the hydrochloride and the crystal thereof have relatively good solubility, stability, oral absorption bioavailability, and druggability.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023213780B2
Jurisdiction
AU
Classification
Expires
2025-11-13
Drug substance claim
No
Drug product claim
No
Assignee
Chengdu Henghao Innovative Science And Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.